These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 14971886

  • 1. New class of corticotropin-releasing factor (CRF) antagonists: small peptides having high binding affinity for CRF receptor.
    Yamada Y, Mizutani K, Mizusawa Y, Hantani Y, Tanaka M, Tanaka Y, Tomimoto M, Sugawara M, Imai N, Yamada H, Okajima N, Haruta J.
    J Med Chem; 2004 Feb 26; 47(5):1075-8. PubMed ID: 14971886
    [Abstract] [Full Text] [Related]

  • 2. Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges.
    Koerber SC, Gulyas J, Lahrichi SL, Corrigan A, Craig AG, Rivier C, Vale W, Rivier J.
    J Med Chem; 1998 Dec 03; 41(25):5002-11. PubMed ID: 9836618
    [Abstract] [Full Text] [Related]

  • 3. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR, Sullivan SK, Schwarz DA, Ling N, Vale WW, Crowe PD, Grigoriadis DE.
    Biochemistry; 2004 Apr 06; 43(13):3996-4011. PubMed ID: 15049707
    [Abstract] [Full Text] [Related]

  • 4. Structure-activity studies on the corticotropin releasing factor antagonist astressin, leading to a minimal sequence necessary for antagonistic activity.
    Rijkers DT, Kruijtzer JA, van Oostenbrugge M, Ronken E, den Hartog JA, Liskamp RM.
    Chembiochem; 2004 Mar 05; 5(3):340-8. PubMed ID: 14997526
    [Abstract] [Full Text] [Related]

  • 5. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C, Wilcoxen KM, Huang CQ, Xie YF, McCarthy JR, Webb TR, Zhu YF, Saunders J, Liu XJ, Chen TK, Bozigian H, Grigoriadis DE.
    J Med Chem; 2004 Sep 09; 47(19):4787-98. PubMed ID: 15341493
    [Abstract] [Full Text] [Related]

  • 6. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
    Dautzenberg FM, Wille S.
    Regul Pept; 2004 May 15; 118(3):165-73. PubMed ID: 15003833
    [Abstract] [Full Text] [Related]

  • 7. Minimal-size, constrained corticotropin-releasing factor agonists with i-(i+3) Glu-Lys and Lys-Glu bridges.
    Rivier J, Lahrichi SL, Gulyas J, Erchegyi J, Koerber SC, Craig AG, Corrigan A, Rivier C, Vale W.
    J Med Chem; 1998 Jul 02; 41(14):2614-20. PubMed ID: 9651165
    [Abstract] [Full Text] [Related]

  • 8. [¹²⁵I]YP20: a novel radioligand specific for the extracellular domain of the CRF₁ receptor.
    Gordon JC, Edwards P, Elmore CS, Lazor LA, Paschetto K, Bostwick R, Sylvester M, Mauger R, Scott C, Aharony D.
    Eur J Pharmacol; 2010 Dec 15; 649(1-3):59-63. PubMed ID: 20854803
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and biological activity of N-terminal lipidated and/or fluorescently labeled conjugates of astressin as corticotropin releasing factor antagonists.
    Rijkers DT, den Hartog JA, Liskamp RM.
    Bioorg Med Chem; 2004 Oct 01; 12(19):5099-106. PubMed ID: 15351393
    [Abstract] [Full Text] [Related]

  • 10. A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor.
    Beyermann M, Fechner K, Furkert J, Krause E, Bienert M.
    J Med Chem; 1996 Aug 16; 39(17):3324-30. PubMed ID: 8765516
    [Abstract] [Full Text] [Related]

  • 11. Astressin analogues (corticotropin-releasing factor antagonists) with extended duration of action in the rat.
    Rivier J, Gulyas J, Corrigan A, Martinez V, Craig AG, Taché Y, Vale W, Rivier C.
    J Med Chem; 1998 Dec 03; 41(25):5012-9. PubMed ID: 9836619
    [Abstract] [Full Text] [Related]

  • 12. Determinants of corticotropin releasing factor. Receptor selectivity of corticotropin releasing factor related peptides.
    Mazur AW, Wang F, Tscheiner M, Donnelly E, Isfort RJ.
    J Med Chem; 2004 Jun 17; 47(13):3450-4. PubMed ID: 15189041
    [Abstract] [Full Text] [Related]

  • 13. Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists.
    Gross RS, Guo Z, Dyck B, Coon T, Huang CQ, Lowe RF, Marinkovic D, Moorjani M, Nelson J, Zamani-Kord S, Grigoriadis DE, Hoare SR, Crowe PD, Bu JH, Haddach M, McCarthy J, Saunders J, Sullivan R, Chen T, Williams JP.
    J Med Chem; 2005 Sep 08; 48(18):5780-93. PubMed ID: 16134945
    [Abstract] [Full Text] [Related]

  • 14. Corticotropin releasing factor (CRF) agonists with reduced amide bonds and Ser7 substitutions.
    Cervini L, Theobald P, Corrigan A, Craig AG, Rivier C, Vale W, Rivier J.
    J Med Chem; 1999 Feb 25; 42(4):761-8. PubMed ID: 10052982
    [Abstract] [Full Text] [Related]

  • 15. Constrained corticotropin-releasing factor antagonists with i-(i + 3) Glu-Lys bridges.
    Miranda A, Lahrichi SL, Gulyas J, Koerber SC, Craig AG, Corrigan A, Rivier C, Vale W, Rivier J.
    J Med Chem; 1997 Oct 24; 40(22):3651-8. PubMed ID: 9357532
    [Abstract] [Full Text] [Related]

  • 16. 3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design.
    Ye Y, Liao Q, Wei J, Gao Q.
    Neurochem Int; 2010 Jan 24; 56(1):107-17. PubMed ID: 19782115
    [Abstract] [Full Text] [Related]

  • 17. An optimized solid phase synthesis strategy--including on-resin lactamization--of astressin, its retro-, inverso-, and retro-inverso isomers as corticotropin releasing factor antagonists.
    Rijkers DT, den Hartog JA, Liskamp RM.
    Biopolymers; 2002 Feb 24; 63(2):141-9. PubMed ID: 11787002
    [Abstract] [Full Text] [Related]

  • 18. Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility.
    Chen C, Wilcoxen KM, Huang CQ, McCarthy JR, Chen T, Grigoriadis DE.
    Bioorg Med Chem Lett; 2004 Jul 16; 14(14):3669-73. PubMed ID: 15203140
    [Abstract] [Full Text] [Related]

  • 19. Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences.
    Dautzenberg FM, Py-Lang G, Higelin J, Fischer C, Wright MB, Huber G.
    J Pharmacol Exp Ther; 2001 Jan 16; 296(1):113-20. PubMed ID: 11123370
    [Abstract] [Full Text] [Related]

  • 20. Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding.
    Gkountelias K, Tselios T, Venihaki M, Deraos G, Lazaridis I, Rassouli O, Gravanis A, Liapakis G.
    Mol Pharmacol; 2009 Apr 16; 75(4):793-800. PubMed ID: 19124613
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.